Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.
Breakthrough Therapy | MindMed's MM120, an LSD-based compound, shows promise in treating Generalized Anxiety Disorder with rapid onset and lasting effects |
Market Potential | Analysts project peak U.S. sales of $1.6 billion for MM120, with potential revenue reaching $2.29 billion by 2031 in the multi-billion-dollar GAD market |
Regulatory Landscape | FDA's Breakthrough Therapy Designation for MM120 could expedite development, reducing regulatory risks and attracting investor interest |
Financial Outlook | Analyst price targets range from $16 to $55, reflecting significant upside potential despite current unprofitability in this clinical-stage company |
Metrics to compare | MNMD | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMNMDPeersSector | |
---|---|---|---|---|
P/E Ratio | −6.5x | −0.9x | −0.5x | |
PEG Ratio | −0.22 | 0.00 | 0.00 | |
Price/Book | 4.0x | 2.5x | 2.6x | |
Price / LTM Sales | - | 1.8x | 3.3x | |
Upside (Analyst Target) | 108.1% | 230.5% | 43.3% | |
Fair Value Upside | Unlock | 4.7% | 6.9% | Unlock |